2023 annual financial data
Ernexa Therapeutics 2023 Operating margin
Direct answer
Operating margin was -31,080.88%.
Operating income was -21,135,000 USD and net income was -21,668,000 USD.
Operating cash flow was -20,408,000 USD.
Get free Ernexa Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 68,000 USD
- Operating income
- -21,135,000 USD
- Net income
- -21,668,000 USD
- Operating cash flow
- -20,408,000 USD